Multi-Year Multi-Indication Agreements for Supporting Patient Access to Oncology Medicines with Multiple Indications: An Experimental Approach or Here to Stay? [0.03%]
支持多适应症抗癌药物患者用药通道的多年多适应症协议：实验方法还是长久之计？
Hannah Armstrong,Angelina Petrova,Tim Wilsdon et al.
Hannah Armstrong et al.
Over the past decade, an increasing number of oncology medicines with indications for multiple cancer types have been delivering benefits to patients. To ensure these products reach patients, pricing and reimbursement systems have had to ad...
Musculoskeletal Magazine Advertising Focuses on White Individuals and Overlooks Minority Consumers [0.03%]
肌肉骨骼杂志广告关注白人，忽视少数族裔消费者
Wei Shao Tung,Kelsey A Rankin,Robert John Oris et al.
Wei Shao Tung et al.
Introduction: Demographic disparities in musculoskeletal (MSK) health exist in the US. Racial representation in advertising has been shown to influence consumer behavior and buying patterns. Direct-to-consumer advertising...
Healthcare Resource Utilization (HCRU) and Direct Medical Costs Associated with Long COVID or Post-COVID-19 Conditions: Findings from a Literature Review [0.03%]
长期新冠或新冠后症状的卫生资源利用和直接医疗费用：文献回顾的结果
Elżbieta Łukomska,Krzysztof Kloc,Malwina Kowalska et al.
Elżbieta Łukomska et al.
Approximately 10-20% of individuals suffering from COVID-19 develop prolonged symptoms known as long COVID or post-COVID condition (LC). This review aimed to assess healthcare resource use (HCRU) and healthcare costs associated with LC. Bec...
The EU Health Technology Assessment Regulation Halo Effect: Are Cross-Functional Teams Ready? [0.03%]
欧盟医学科技评估法规的辐射效应：跨职能团队准备好了吗？
Sian Tanner,Rebecca Coady,Ana Lisica et al.
Sian Tanner et al.
The focus of manufacturers preparing for implementation of the EU HTA Regulation (HTAR) in 2025 has understandably been on their market access teams, and how they can be best equipped to adapt to this significant change. Considering the cri...
Assessing the Value of Further Investment in R&D Using Mixed Methods: A Case Study of Biosensor-Integrated Arteriovenous Grafts [0.03%]
基于混合研究方法的进一步投资价值评估——以集成生物传感器的动静脉内瘘为例
Samuel Owusu Achiaw,Neil Hawkins,Olivia Wu et al.
Samuel Owusu Achiaw et al.
This study illustrates the utility of a mixed-methods approach in assessing the value of an example novel technology-biosensor-integrated self-reporting arteriovenous grafts (smart AVGs). Currently in preclinical development, the device wil...
Gatekeeping or Provider Choice for Sustainable Health Systems? A Literature Review on Their Impact on Efficiency, Access, and Quality of Services [0.03%]
把关与提供者选择：对效率、准入及服务质量的影响——文献回顾
Christos Ntais,Nikolaos Kontodimopoulos,Michael A Talias
Christos Ntais
As early as 1978, the World Health Organization set primary healthcare as the basis on which health systems should be built worldwide. However, the health systems of the different countries show considerable variations in terms of the imple...
Managing Pharmaceutical Costs in Health Systems: A Review of Affordability, Accessibility and Sustainability Strategies [0.03%]
卫生系统中的医药费用管控：可负担性、可及性和可持续性策略综述
Christos Ntais,Michael A Talias,John Fanourgiakis et al.
Christos Ntais et al.
Background: This paper reviews cost containment policies to control pharmaceutical expenditure either by regulating the pharmaceutical industry or targeting the demand side. ...
Operational Efficiency of Public Hospitals in Greece During the COVID-19 Pandemic: A Comparative Analysis Using DEA and AHP Models [0.03%]
新冠疫情下的希腊公立医院运营效率：基于DEA和AHP模型的比较分析
Athanasios Mitakos,Panagiotis Mpogiatzidis
Athanasios Mitakos
This study evaluates the efficiency of public hospitals in Greece during the COVID-19 epidemic in 2020, using Data Envelopment Analysis (DEA) and the Analytical Hierarchy Process (AHP). Faced with unprecedented pressure from increased deman...
Clinical Benefits of Sustained Oral Nirmatrelvir/Ritonavir Use for the Outpatient Treatment of COVID-19: Findings from the Taiwanese Health Authority Perspective Using a Decision Tree Modeling Approach [0.03%]
持续口服奈玛特韦/利托那韦治疗新冠肺炎患者门诊临床获益：基于台湾地区卫生行政部门视角的决策树模型结果分析
Matthew Sussman,Jennifer Benner,Tendai Mugwagwa et al.
Matthew Sussman et al.
Despite the observed clinical benefits of nirmatrelvir/ritonavir (NMV/r), it is uncertain whether Taiwan will continue covering NMV/r for high-risk individuals with mild-to-moderate coronavirus disease 2019 (COVID-19). This analysis assesse...